Relebactam
Based on 31 publication(s) in Google Scholar
Relebactam is a diazabicyclooctane inhibitor with activity against a wide spectrum of β-lactamases, including class A (extended-spectrum β-lactamases and KPC) and class C (AmpC) enzymes. Relebactam shows antibacterial activity.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.95%
- CAS No.: 1174018-99-5
- 화학식: C12H20N4O6S
- 분자량:348.38
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Covalent Screening Library
HY-L036
-
Antibacterial Compound Library
HY-L049
-
Anti-COVID-19 Compound Library
HY-L052
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
EMA-Approved Drug Library
HY-L116
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Relebactam
More- Antibiotics (Basel). 2021 Nov 3;10(11):1341. [Abstract]
- Int J Antimicrob Agents. 2025 Jun 4:107550. [Abstract]
- Int J Antimicrob Agents. 2024 May 14:107206. [Abstract]
- Int J Antimicrob Agents. 2022 Nov-Dec;60(5-6):106669. [Abstract]
- Sci Rep. 2022 Oct 7;12(1):16814. [Abstract]
- ACS Infect Dis. 2024 May 10;10(5):1624-1643. [Abstract]
- ACS Infect Dis. 2021 Apr 9;7(4):826-837. [Abstract]
- Antimicrob Agents Chemother. 2026 Jun 3;70(6):e0126725. [Abstract]
- Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0077524. [Abstract]
- Antimicrob Agents Chemother. 2024 Aug 19:e0069324. [Abstract]
- Antimicrob Agents Chemother. 2023 Dec 14;67(12):e0034623. [Abstract]
- Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0033923. [Abstract]
- Antimicrob Agents Chemother. 2023 Jun 15;67(6):e0160322. [Abstract]
- Antimicrob Agents Chemother. 2020 Nov 17;64(12):e00297-20. [Abstract]
- Antimicrob Agents Chemother. 2020 Mar 24;64(4):e02255-19. [Abstract]
- J Antimicrob Chemother. 2026 Feb 2;81(3):dkag034. [Abstract]
- J Antimicrob Chemother. 2025 Nov 5:dkaf408. [Abstract]
- Microbiol Spectr. 2023 Dec 12;11(6):e0304723. [Abstract]
- Microbiol Spectr. 2023 Jun 15;11(3):e0069223. [Abstract]
- Microbiol Spectr. 2023 Feb 14;11(1):e0303822. [Abstract]
- J Antimicrob Chemother. 2021 Jul 15;76(8):2071-2078. [Abstract]
- J Antimicrob Chemother. 2021 Feb 11;76(3):653-658. [Abstract]
- J Glob Antimicrob Resist. 2026 Jun 24:S2213-7165(26)00094-9. [Abstract]
- J Glob Antimicrob Resist. 2022 Dec:31:1-9. [Abstract]
- Eur J Clin Microbiol Infect Dis. 2025 Mar;44(3):571-585. [Abstract]
- Eur J Clin Microbiol Infect Dis. 2025 Feb;44(2):277-284. [Abstract]
- Infect Drug Resist. 2020 Aug 18;13:2883-2890. [Abstract]
- Diagn Microbiol Infect Dis. 2024 Dec;110(4):116474. [Abstract]
- bioRxiv. 2025 January 21.
- Res Sq. 2024 Nov 26.
- bioRxiv. 2021 Mar 13.
Customer Validation & Images
-
Microbiological Assay
-
Bio/Physico-chemical Assay
-
Microbiological Assay
-
Microbiological Assay
-
Microbiological Assay
All Beta-lactamase Isoforms
More
Biological Activity
Relebactam combine with Imipenem demonstrates activity against KPC-producing Enterobacteriaceae and multidrug-resistant P. aeruginosa[1].
Relebactam shows limited inhibition of Class D-producing bacteria and has antipseudomonal activity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1174018-99-5
-
Appearance Solid
-
분자량 348.38
-
화학식 C12H20N4O6S
-
Color White to off-white
-
SMILES
O=S(ON1[C@]2([H])CC[C@@H](C(NC3CCNCC3)=O)[N@@](C2)C1=O)(O)=O
-
Synonyms
MK-7655
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (31)
-
Journal Impact Factor
-
Most Recent
-
Antibiotics (Basel)
Antimicrobial Activity of Aztreonam in Combination with Old and New β-Lactamase Inhibitors against MBL and ESBL Co-Producing Gram-Negative Clinical Isolates: Possible Options for the Treatment of Complicated Infections. [Abstract]2021 Nov 3;10(11):1341. PMID: 34827279
Relebactam purchased from MedChemExpress. Usage Cited in: Antibiotics (Basel). 2021 Nov 3;10(11):1341. [Abstract]
Twenty-four-hour time–kill curves of aztreonam (ATM) and relebactam (REL), alone and in combination, on: C. amalonaticus N18; K. pneumoniae KL 12 SG; K. pneumoniae LC954/14.
-
Int J Antimicrob Agents
In vitro activity of cefepime-zidebactam, ceftolozane-tazobactam, ceftazidime-avibactam, imipenem-relebactam, and other comparators against imipenem-non-susceptible Pseudomonas aeruginosa in Taiwan, 2022. [Abstract]2025 Jun 4:107550. PMID: 40480535 -
Int J Antimicrob Agents
MultiRapid ATB NP test for detecting concomitantly susceptibility and resistance of last resort novel antibiotics available to treat multidrug-resistant Enterobacterales infections. [Abstract]2024 May 14:107206. PMID: 38754526
Relebactam purchased from MedChemExpress. Usage Cited in: Int J Antimicrob Agents. 2024 May 14:107206. [Abstract]
The MultiRapid ATB NP test. Column D shows the solution with imipenem–relebactam (IPR, 12/4 mg/L);. Reference strain Escherichia coli ATCC 25922 was inoculated in wells A1–F1; Positive control resistant to all the antibiotics was inoculated in wells A2–F2; First tested strain (resistant to CZA, MEV, and IPR) was inoculated in wells A3–F3; Second tested strain (resistant to CZA and FDC) was inoculated in wells A4–F4; and NaCl 0.85% was inoculated in wells A5–F5. Bacterial growth is shown by a colour change of the medium from red to yellow.
-
Int J Antimicrob Agents
In vitro effects of diazabicyclooctane β-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex. [Abstract]2022 Nov-Dec;60(5-6):106669. PMID: 36064079
Relebactam purchased from MedChemExpress. Usage Cited in: Int J Antimicrob Agents. 2022 Nov-Dec;60(5-6):106669. [Abstract]
The MICs of seven β-lactams with relebactam 8 mg/L against M. abscessus.
Relebactam purchased from MedChemExpress. Usage Cited in: Int J Antimicrob Agents. 2022 Nov-Dec;60(5-6):106669. [Abstract]
The MICs of seven β-lactams with relebactam 8 mg/L against M. massiliense.
-
Sci Rep
Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa. [Abstract]2022 Oct 7;12(1):16814. PMID: 36207358 -
ACS Infect Dis
3- O-Substituted Quercetin: an Antibiotic-Potentiating Agent against Multidrug-Resistant Gram-Negative Enterobacteriaceae through Simultaneous Inhibition of Efflux Pump and Broad-Spectrum Carbapenemases. [Abstract]2024 May 10;10(5):1624-1643. PMID: 38652574 -
ACS Infect Dis
Assessing the Potency of β-Lactamase Inhibitors with Diverse Inactivation Mechanisms against the PenA1 Carbapenemase from Burkholderia multivorans. [Abstract]2021 Apr 9;7(4):826-837. PMID: 33723985 -
Antimicrob Agents Chemother
Improved hydrolysis of piperacillin by OXA-48-like R214G variants, a selective advantage under piperacillin-tazobactam exposure. [Abstract]2026 Jun 3;70(6):e0126725. PMID: 42053451 -
Antimicrob Agents Chemother
Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone β-lactamase inhibitors against broad-spectrum AmpC β-lactamases. [Abstract]2024 Nov 6;68(11):e0077524. PMID: 39365068 -
Antimicrob Agents Chemother
Multicenter evaluation of activity of aztreonam in combination with avibactam, relebactam, and vaborbactam against metallo-β-lactamase-producing carbapenem-resistant gram-negative bacilli. [Abstract]2024 Aug 19:e0069324. PMID: 39158279 -
Antimicrob Agents Chemother
In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates. [Abstract]2023 Dec 14;67(12):e0034623. PMID: 37971240 -
Antimicrob Agents Chemother
Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa. [Abstract]2023 Jul 18;67(7):e0033923. PMID: 37255469 -
Antimicrob Agents Chemother
Penicillin-Binding Protein 5/6 Acting as a Decoy Target in Pseudomonas aeruginosa Identified by Whole-Cell Receptor Binding and Quantitative Systems Pharmacology. [Abstract]2023 Jun 15;67(6):e0160322. PMID: 37199612
Relebactam purchased from MedChemExpress. Usage Cited in: Antimicrob Agents Chemother. 2023 Jun 15;67(6):e0160322. [Abstract]
Difference between whole cells and isolated PBPs fraction unbound. P. aeruginosa PAO1 cultures (whole cells) and PBP-containing membrane preparations (isolated) were incubated for 15, 30, and 60 min in the presence of relebactam (REL), and afterwards isolated PBPs labeled with 25 μM Boc-FL.
-
Antimicrob Agents Chemother
Activity of Aztreonam in Combination with Avibactam, Clavulanate, Relebactam, and Vaborbactam against Multidrug-Resistant Stenotrophomonas maltophilia. [Abstract]2020 Nov 17;64(12):e00297-20. PMID: 32928733 -
Antimicrob Agents Chemother
Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens. [Abstract]2020 Mar 24;64(4):e02255-19. PMID: 31932381 -
J Antimicrob Chemother
Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study. [Abstract]2026 Feb 2;81(3):dkag034. PMID: 41648989 -
J Antimicrob Chemother
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction. [Abstract]2025 Nov 5:dkaf408. PMID: 41206063 -
Microbiol Spectr
In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from cystic fibrosis patients. [Abstract]2023 Dec 12;11(6):e0304723. PMID: 37982634 -
Microbiol Spectr
Penicillin-Binding Protein Occupancy Dataset for 18 β-Lactams and 4 β-Lactamase Inhibitors in Neisseria gonorrhoeae. [Abstract]2023 Jun 15;11(3):e0069223. PMID: 37093051 -
Microbiol Spectr
PBP Target Profiling by β-Lactam and β-Lactamase Inhibitors in Intact Pseudomonas aeruginosa: Effects of the Intrinsic and Acquired Resistance Determinants on the Periplasmic Drug Availability. [Abstract]2023 Feb 14;11(1):e0303822. PMID: 36475840 -
J Antimicrob Chemother
In vitro activity of imipenem/relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. [Abstract]2021 Jul 15;76(8):2071-2078. PMID: 33956969 -
J Antimicrob Chemother
Susceptibility of Elizabethkingia spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods. [Abstract]2021 Feb 11;76(3):653-658. PMID: 33258923 -
J Glob Antimicrob Resist
In vitro activity of cefiderocol against clinically relevant Gram-negative bacilli collected in China in 2023. [Abstract]2026 Jun 24:S2213-7165(26)00094-9. PMID: 42342122 -
J Glob Antimicrob Resist
In vitro and in vivo activities of a novel β-lactamase inhibitor combination imipenem/XNW4107 against recent clinical Gram-negative bacilli from China. [Abstract]2022 Dec:31:1-9. PMID: 35820591 -
Eur J Clin Microbiol Infect Dis
In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022. [Abstract]2025 Mar;44(3):571-585. PMID: 39704920 -
Eur J Clin Microbiol Infect Dis
In-vitro activity of newly-developed β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with anti-pseudomonal β-lactam antibiotics against AmpC-overproducing clinical Pseudomonas aeruginosa isolates. [Abstract]2025 Feb;44(2):277-284. PMID: 39589655 -
Infect Drug Resist
Zinc Chelator N,N,N',N'-Tetrakis(2-Pyridylmethyl)Ethylenediamine Reduces the Resistance of Mycobacterium abscessus to Imipenem. [Abstract]2020 Aug 18;13:2883-2890. PMID: 32903882 -
Diagn Microbiol Infect Dis
Rapid detection of imipenem/relebactam susceptibility/resistance in Pseudomonas aeruginosa. [Abstract]2024 Dec;110(4):116474. PMID: 39191152 -
-
-
용액&용해도
DMSO : 175 mg/mL (502.33 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 50 mg/mL (143.52 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 25 mg/mL (71.76 mM); Clear solution; Need ultrasonic
순도&문서
-
Data Sheet (273 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lapuebla A, et al. Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City. Antimicrob Agents Chemother. 2015 Aug;59(8):5029-31. [Content Brief]
[2]. Bush K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents. 2015 Nov;46(5):483-93. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 2.8704 mL | 14.3521 mL | 28.7043 mL | 71.7607 mL |
| 5 mM | 0.5741 mL | 2.8704 mL | 5.7409 mL | 14.3521 mL | |
| 10 mM | 0.2870 mL | 1.4352 mL | 2.8704 mL | 7.1761 mL | |
| 15 mM | 0.1914 mL | 0.9568 mL | 1.9136 mL | 4.7840 mL | |
| 20 mM | 0.1435 mL | 0.7176 mL | 1.4352 mL | 3.5880 mL | |
| 25 mM | 0.1148 mL | 0.5741 mL | 1.1482 mL | 2.8704 mL | |
| 30 mM | 0.0957 mL | 0.4784 mL | 0.9568 mL | 2.3920 mL | |
| 40 mM | 0.0718 mL | 0.3588 mL | 0.7176 mL | 1.7940 mL | |
| 50 mM | 0.0574 mL | 0.2870 mL | 0.5741 mL | 1.4352 mL | |
| 60 mM | 0.0478 mL | 0.2392 mL | 0.4784 mL | 1.1960 mL | |
| 80 mM | 0.0359 mL | 0.1794 mL | 0.3588 mL | 0.8970 mL | |
| 100 mM | 0.0287 mL | 0.1435 mL | 0.2870 mL | 0.7176 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Relebactam Related Classifications
HY-16752 Related Classifications
Powered by Bioz